Best Nanotech Penny Stock to Buy
 | A Message on Behalf of NanoViricides, Inc. | Biotech Innovator on the NYSE Announces Breakthrough Antiviral Therapy! |  | What's in store for biotech in 2025? A lot of good!
As biotech stages a big comeback, NanoViricides, Inc. (NYSE:NNVC) looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.
NanoViricides, Inc. (NYSE:NNVC) is a global leader in the application of nanomedicine technologies to the safe and effective treatment of viruses and their variants INCLUDING drugs against Covid-19, RSV and other respiratory viruses!
Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031*
Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known viruses. The Company is developing broad-spectrum nanoviricides to combat several diseases: NV-387 combats RSV, COVID-19, Flu and Smallpox; NV-HHV-1 combats Shingles and others in the Herpes Family; other Nanoviricides™ combat other diseases like Dengue, Rabies, and Ebola/Marburg. This versatility is similar to antibiotics such as penicillin that exploit a feature common to all bacteria when they cure any bacterial infection.
ANTIBODIES AND VACCINES ARE OUTDATED: NanoViricides has a more innovative approach that works even when viruses mutate!!! |
| | Access the Latest Report Now! |
| This message is a paid advertisement for NanoViricides, Inc. from Interactive Offers. Schaeffer's Investment Research Inc. receives a fixed fee for each subscriber that clicks on a link in this email. Other than the compensation received for this advertisement sent to subscribers, Schaeffer's Investment Research Inc. and its principals are not affiliated with NanoViricides, Inc. Schaeffer's Investment Research Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Schaeffer's Investment Research Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Schaeffer's Investment Research Inc. to buy or sell any security. Schaeffer's Investment Research Inc. has not evaluated the accuracy of any claims made in this advertisement. Schaeffer's Investment Research Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. on NanoViricides, Inc. website for additional information. |
|
|
|
|
No comments:
Post a Comment